Ligament Lesions: Biologics

dc.creatorFigueroa, David
dc.creatorGuiloff, Rodrigo
dc.creatorFigueroa, Francisco
dc.date.accessioned2023-01-09T18:08:54Z
dc.date.accessioned2023-05-19T14:52:37Z
dc.date.available2023-01-09T18:08:54Z
dc.date.available2023-05-19T14:52:37Z
dc.date.created2023-01-09T18:08:54Z
dc.date.issued2022
dc.identifierFigueroa, D., Guiloff, R., Figueroa, F. (2022). Ligament Lesions: Biologics. In: Filardo, G., Mandelbaum, B.R., Muschler, G.F., Rodeo, S.A., Nakamura, N. (eds) Orthobiologics. Springer, Cham. https://doi.org/10.1007/978-3-030-84744-9_21
dc.identifierhttps://doi.org/10.1007/978-3-030-84744-9_21
dc.identifierhttps://repositorio.udd.cl/handle/11447/6907
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6303297
dc.description.abstractIn terms of the latest clinical evidence, the use of PRP for ligament injuries remains controversial. There is insufficient evidence to recommend the use of PRP in ACL-R for improving graft maturation and donor site morbidity or improving functional outcomes. The use of PRP injections for the treatment of partial ACL injuries, MCL injuries, and ankle sprains cannot be recommended. Finally, there is no reported clinical evidence of the use of PRP in other knee ligament injuries such as posterior cruciate ligament, lateral collateral ligament, and posterolateral corner
dc.languageen
dc.subjectPlatelet-rich plasma
dc.subjectAnterior Cruciate Ligament Injuries
dc.subjectLigament lesions
dc.titleLigament Lesions: Biologics
dc.typeBook chapter


Este ítem pertenece a la siguiente institución